Phoenix, AZ (Uptick Newswire – February 21, 2018) – SANUWAVE Health, Inc. (OTCQB: SNWV) (“the Company”), today announced CEO Kevin Richardson’s interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
“SANUWAVE Health is an exciting company, with a skilled management team that has created an efficient business model producing impressive results,” said Jolly. “DermaPACE, the company’s flagship device in the medical field, received FDA approval in December 2017 and the first procedure should be underway by the end of next week.”
SANUWAVE Health recently received FDA approval for dermaPACE, a state of the art device that treats diabetic foot ulcers and is compatible with a host of other products. The company is working both domestically and abroad, with seven countries in the pipeline and a joint venture with Brazil.
“We are not reinventing the wheel,” Richardson commented. “We have a business model that has proven successful and are executing on each goal. The company is very research intensive and have a total of 69 patents and patents pending.”
To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview-ceo-kevin-richardson-of-sanuwave-health-inc-otcqb-snwv-2
SANUWAVE also received a Valuation of $0.55 from Zachs Small-Cap Research. To view the full report please click here: SNWV_Premier. Equip Fin 02.16.2018
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick
Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook for additional radio and video shows produced by Uptick! https://www.youtube.com/watch?v=kU5SVLp4org
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit SANUWAVE Health’s message board on: https://investorshangout.com/Sanuwave-Health-Inc-SNWV-66973/
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Millennium Park Capital LLC
SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
Source: Uptick Newswire